Erwin R. Boghaert
AbbVie (United States)(US)
Publications by Year
Research Areas
Cancer Cells and Metastasis, 3D Printing in Biomedical Research, Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies(2003)354 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models(2016)308 cited
- → Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery(2016)241 cited